Genome Therapeutics to Present at the Annual BIO CEO & Investor Conference.Business Editors & Health/Medical Writers BIO CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. & Investor Conference 2003 WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 13, 2003 Genome Therapeutics' (Nasdaq: GENE) President and Chief Executive Officer, Steven M. Rauscher, will deliver a company presentation at the 2003 BIO CEO & Investor Conference on Wednesday, February 26, 2003 at 4:00 PM ET in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. . Mr. Rauscher's talk will highlight the Company's clinical development program for its anti-infective candidate Ramoplanin and recently initiated collaborations, as well as provide commentary about the Company's business strategy and anticipated milestones in the coming months. The presentation will be available on February 26 at www.genomecorp.com and will be archived for 90 days. More information about the conference and the Biotechnology Industry Organization Biotechnology Industry Organization or BIO was founded 1993 in Washington, DC. James C. Greenwood is BIO's current President. External links
Genome Therapeutics is a biopharmaceutical company focused on the discovery and development of pharmaceutical and diagnostics products. The Company's first product candidate, Ramoplanin, is in a Phase III clinical trial Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the for the prevention of bloodstream infections caused by vancomycin-resistant enterococci (VRE VRE vancomycin-resistant enterococcus. VRE Vancomycin-resistent enterococcus, see there ). Genome Therapeutics' biopharmaceutical business includes seven major product discovery alliances with several pharmaceutical companies including Schering-Plough, AstraZeneca, Wyeth, Amgen and bioMerieux. The Company's genomics services business, GenomeVision(TM) Services, provides pharmaceutical and biotechnology companies, and government and academic institutions with custom high-throughput sequencing, library construction, integrated SNP SNP Scottish National Party Noun 1. SNP - (genetics) genetic variation in a DNA sequence that occurs when a single nucleotide in a genome is altered; SNPs are usually considered to be point mutations that have been evolutionarily services and the PathoGenome(TM) Database. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion